CMMB · Chemomab Therapeutics Ltd.
$1.91
+0.01 (+0.53%)
At close · Aug 14
Market Cap
$14.07M
Shares
7.33M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Dr. Nissim Darvish | Chairman of the Board | Appointed | 2023-06-05 |
| Ms. Sigal Fattal | Chief Financial Officer | Appointed | 2023-06-05 |
| Dr. Adi Mor | Chief Executive Officer | Appointed | 2023-06-05 |
| Stephen Squinto | director | Resigned | 2021-12-16 |
| Stephen Squinto | chairman of the Board | Resigned | 2021-12-16 |
| David M. Weiner | Interim Chief Medical Officer | Appointed | 2021-12-03 |
| Arnon Aharon | Chief Medical Officer | Resigned | 2021-12-03 |
| Donald Marvin | Chief Operating Officer | Appointed | 2021-11-08 |
| Donald Marvin | Chief Financial Officer, Executive Vice President and Chief Operating Officer | Appointed | 2021-11-08 |
Key facts
CIK
1534248
CUSIP
16385C203
13F (30d)
13 filings
13 filers
Visit website
Investor relations